OBJECTIVE— Diabetic individuals have impaired endothelium-dependent forearm vasodilatory responses to ischemia, acetylcholine, and other endothelium-dependent agonists. The functional significance of impaired endothelium-dependent dilation in diabetic individuals is uncertain but is most likely to be manifest during leg muscle exercise and may have relevance to peripheral vascular disease and leg ischemia, which is prevalent in diabetic individuals. The current study aimed to determine the relationship between leg blood flow (LBF) responses to endothelium-dependent vasodilation and dynamic large muscle exercise.

RESEARCH DESIGN AND METHODS— LBF responses (thermodilution) to intrafemoral arterial infusions of an endothelium-dependent (acetylcholine) and endothelium-independent (sodium nitroprusside) vasodilator and a standardized 25-min cycling bout at 60% Vo2peak were compared in nine male type 2 diabetic subjects and nine age-, sex-, Vo2peak-, and weight-matched control subjects.

RESULTS— LBF responses to acetylcholine and exercise but not sodium nitroprusside were significantly (P < 0.05) attenuated in patients with diabetes compared with healthy control subjects. The percentage increase in LBF in response to exercise and acetylcholine were significantly correlated (r = 0.54, P = 0.02). Furthermore, resting plasma glucose was significantly related to the LBF response to exercise (r = −0.66, P = 0.003) independently of insulin, HbA1c, lipids, BMI, and blood pressure.

CONCLUSIONS— The increase in LBF during exercise is substantially attenuated in type 2 diabetic compared with matched control subjects. Impaired endothelium-dependent vasodilation secondary to elevated plasma glucose may underlie this observation. This mechanism may be of importance in determining the leg ischemic threshold in diabetic individuals with peripheral vascular disease.

Type 2 diabetic individuals have impaired dilatory responses to endothelium-dependent agonists such as acetylcholine (1) and methacholine (2,3). Furthermore, forearm flow–mediated dilation is reduced in type 2 diabetic individuals, especially those with peripheral vascular disease (4). There are many possible mediators of endothelial dysfunction in patients with type 2 diabetes. In established disease, it is likely that damage associated with advanced glycosylation end products is most important. In individuals with milder diabetes, dyslipidemia, hypertension, hyperinsulinemia, and hyperglycemia may all contribute. The clinical relevance of impaired endothelium-dependent vasodilation is as an early marker of cardiovascular risk, which may contribute to the atherosclerotic disease process (5). Endothelial-dependent vasodilation may also have relevance to blood flow control during exercise. Specifically, endothelium-derived vasodilator prostanoids and nitric oxide (NO) have been proposed to contribute to exercise hyperemia (610). Thus, endothelial dysfunction may also have clinical relevance to leg ischemic threshold in patients with peripheral vascular disease. However, the importance of impaired endothelium-dependent vasodilation with respect to blood flow control during exercise in the early development of diabetes is not known.

The current study examined the relationship between leg blood flow (LBF) responses to endothelium-dependent vasodilation and dynamic large muscle exercise. The leg was studied as a vascular bed relevant to the pathogenesis of atherosclerosis and peripheral vascular disease. Specifically, LBF responses to an endothelium-dependent (acetylcholine) and endothelium-independent (sodium nitroprusside) vasodilator and a standardized exercise bout were compared in type 2 diabetic individuals and age-, sex-, Vo2peak-, and weight-matched healthy control subjects. The hypothesis was that type 2 diabetic individuals would have impaired LBF responses to both exercise and acetylcholine, and that these responses would be related.

Subjects

After providing written informed consent, nine type 2 non–insulin-dependent diabetic men aged 48 ± 4 years (mean ± SD) and nine control subjects (46 ± 5 years) participated in the study, which was approved by the Alfred Hospital ethics committee and conducted in accordance with the Declaration of Helsinki of the World Medical Association. All subjects were nonsmokers, free of overt coronary disease (stress electrocardiogram), and with a BMI of <35 kg/m2. Control subjects did not take any medication and had fasting and post–2-h 75-g oral glucose load plasma glucose levels of <6.1 mmol/l, whereas type 2 diabetic individuals had fasting plasma glucose >7 mmol/l and/or post–75-g oral glucose load plasma glucose levels of >11.1 mmol/l (Table 1) (11,12). Of the diabetic subjects, seven were controlled by diet and two were medicated with metformin. Of those medicated, one was also taking gliclazide. The two medicated diabetic subjects did not take their medication the night before or the morning of the screening or experimental day, and thus they had a 24-h drug-free period before all measurements. Because hypoglycemic agents, in particular metformin, are known to improve endothelial function, the inclusion of medicated patients is unlikely to account for the findings (13). All were normally active but were not specifically exercise trained.

Subject preparation

Peak pulmonary oxygen uptake (Vo2peak) was determined during continuous incremental upright cycling to volitional exhaustion on an electronically braked ergometer (900 ergometer, D-7474; Ergo-line, Bitz, West Germany). Expired air was analyzed for volume, O2, and CO2 using calibrated analyzers (Quark b2; Cosmed, Rome, Italy). During a subsequent visit, subjects were familiarized with supine cycling during a 30-min bout on an electronically braked ergometer (380B ergometry system; Siemens-Elema, Sweden) at a workload eliciting 60% of the upright Vo2peak.

Protocol

LBF was measured at rest and at 3, 4, and 5 min during an intrafemoral artery infusion of acetylcholine (6.4 μg · kg−1 · min−1). After a 30-min rest period to allow LBF to return to resting levels, similar measurements were made in response to sodium nitroprusside (0.2 μg · kg−1 · min−1). Both drugs were delivered at a rate of 2 ml/min. The dose of sodium nitroprusside was calculated so as to elicit LBF responses similar to those observed for acetylcholine in the diabetic patients. LBF was again allowed to return to resting levels over a 30-min period. All subjects performed a 25-min supine cycling bout at 60 ± 2% Vo2peak in the supine position. During this trial, saline was infused at a rate of 2 ml/min between 10 and 25 min of exercise. LBF was measured at rest before exercise and at 10, 15, 20, and 25 min during exercise as part of a previous study (14).

Experimental procedures

Subjects were requested to refrain from exercise, alcohol, and caffeine for 24 h before the experimental trial. After an overnight fast, subjects attended the Alfred Hospital at 0800 h. The right femoral artery and vein were cannulated as described previously (14,15) and used for simultaneous arterial and venous blood sampling, arterial blood pressure measurement, arterial drug infusions, and venous blood flow measurement. Blood pressure, blood temperature, and infusate temperature were digitized, and electronic calipers were used to average these signals over appropriate time intervals.

Preparation of drug infusions

Acetylcholine (Clinalfa; Calbiochem-Novabiochem, Läufalfingen, Switzerland) and sodium nitroprusside (Roche, Basel) were diluted in 0.9% NaCl.

LBF

Right femoral venous blood flow was measured by constant-rate infusion of cold saline according to the thermodilution principle (16), as described previously by our group (14,15). Briefly, cold saline was drawn from a reservoir and then immediately infused through the femoral venous catheter (5–8°C) using a Leibel-Flarsheim Angiomat 3000 Injector (Sybron, Cincinnati, OH). At rest, LBF was measured at an infusion rate of 0.7 ml/s for 20 s. During exercise, LBF was measured using a constant infusion rate between 1.5 and 2.4 ml/s for 15 s, titrated to produce an ∼0.9–1.2°C decrease in blood temperature. The coefficient of variation in blood flow measurement during exercise was 6.7%.

Blood sampling and analysis

Triglycerides, glucose concentration, and plasma total, LDL, and HDL cholesterol were measured using enzymatic spectrophotometric techniques with a Cobas-BIO centrifugal analyzer (Roche Diagnostic Systems). Arterial plasma insulin concentration was measured in duplicate by radioimmunoassay (Linco Research, St. Charles, MO). HbA1c was measured using affinity high-performance liquid chromatography (CLC385 liquid chromatograph with a 234 Autosampler; Primus, Kansas City, MO). This methodology is compatible with that used in the Diabetes Control and Complications Trial.

Statistics

All results are expressed as means ± SE. Group characteristics were compared using unpaired t tests. Serial measurements made during drug infusions and exercise were analyzed using repeated-measures ANOVA to examine differences between groups. A Pearson correlation coefficient was used for univariate analysis. Multiple regression was performed by stepped backward and forward entry. Variables were entered if the respective F probability was <0.05 and were removed if the F probability was >0.1. The null hypothesis was rejected at P ≤ 0.05.

Control and type 2 diabetic subjects were not different in age, weight, or BMI (Table 1). Fasting plasma glucose and triglycerides were significantly higher and HDL cholesterol significantly lower in diabetic subjects (Table 1). HbA1c was higher in diabetic subjects, attesting to their diabetic status, but the elevation was only mild, indicating that they were well controlled. Furthermore, whereas fasting insulin tended to be higher in diabetic subjects, it was not significantly different from control subjects. There was no difference between groups in total or LDL cholesterol (Table 1). All blood pressures were within the normotensive range; however, resting brachial diastolic blood pressure was 6 mmHg higher in patients with diabetes, whereas systolic blood pressure was not different from control subjects (Table 1).

Leg vascular reactivity

Resting LBF was not significantly different between groups (Fig. 1). In healthy control subjects, LBF increased from 0.370 ± 0.034 l/min at rest to an average (mean 3–5 min) of 1.76 ± 0.30 l/min during acetylcholine infusion (an increase of 394 ± 81%) (Fig. 1A). In contrast, the increase in diabetic subjects was significantly less, from 0.279 ± 0.026 to 0.813 ± 0.133 l/min (an increase of 190 ± 36%, P < 0.05 for both absolute LBF and percentage change) (Fig. 1A). There was no significant difference in the LBF response to sodium nitroprusside between the two groups (Fig. 1B). Blood pressure and heart rate were unaffected by drug infusion in both groups.

Exercise hemodynamics

Vo2peak, exercise workload, and exercise Vo2 as a percentage of Vo2peak were not different between groups (Table 1). Furthermore, throughout exercise there was no difference between groups in either leg oxygen consumption, whole-body respiratory exchange ratio, or leg respiratory quotient (14) (Table 1). LBF was not different between control and diabetic subjects before exercise but was significantly lower in diabetic subjects during exercise (mean 10–25 min, control subjects 3.73 ± 0.38 l/min, diabetic subjects 2.78 ± 0.19 l/min, P = 0.04) (Fig. 2A). At rest, there was no difference in heart rate or intrafemoral artery blood pressure between the diabetic and control groups. Heart rate was not different between groups during exercise (Table 1). Both systolic and diastolic blood pressure were higher in diabetic subjects throughout exercise (mean 10–25 min, control subjects 131/68 ± 3/3 mmHg; diabetic subjects 155/79 ± 7/2 mmHg; P < 0.01) (Fig. 2B). As a consequence of both lower LBF and higher blood pressure, leg vascular resistance was higher in diabetic subjects (mean 10–25 min, control subjects 27.9 ± 3.2 mmHg · min−1 · l−1; diabetic subjects 42.5 ± 3.1 mmHg · min−1 · l−1; P = 0.005) (Fig. 2C).

The percentage changes in LBF in response to exercise and acetylcholine were significantly correlated (r = 0.54, P = 0.02) (Fig. 3A). To determine potential influences on the impaired LBF response to both acetylcholine and exercise in diabetic subjects, univariate analysis was used to examine the relationship of these parameters with resting glucose, insulin, HbA1c, HDL cholesterol, triglycerides, diastolic blood pressure, and BMI. There was a significant negative correlation between the LBF response to exercise and fasting plasma glucose (r = −0.66, P = 0.003) (Fig. 3B) and to a lesser extent fasting insulin (r = −0.47, P = 0.05) and BMI (r = −0.49, P = 0.04). There were no significant relationships for the other variables examined. In multiple regression incorporating the significant univariate correlates of exercise LBF, fasting plasma glucose was the only significant independent variable. Relationships with LBF response to acetylcholine were not significant, but there was a trend for a negative relationship with fasting plasma glucose (r = −0.41, P = 0.09).

Impaired endothelium-dependent dilatory responses are thought to be an antecedent to atherosclerosis (17) and peripheral vascular disease (4). The current data attribute functional significance to impaired endothelium-dependent vasodilation, demonstrating that LBF is reduced in type 2 diabetic subjects during exercise and that this response is correlated with impaired responsiveness to acetylcholine. Furthermore, the relationship between LBF response to exercise and fasting plasma glucose suggests that the underlying mechanism relates, at least in part, to hyperglycemia.

Hemodynamics during exercise

This is the first demonstration of a reduced LBF response during exercise in diabetic subjects, and it occurred despite higher perfusion pressure. Peripheral vascular resistance was therefore elevated during exercise in the patients with diabetes, suggesting impairment of normal vasodilatory responses. In the only other similar study of which we are aware, Martin et al. (18) found no difference in exercise LBF between type 2 diabetic and control subjects, probably because of recruitment of a fitter cohort.

Endothelial dysfunction in type 2 diabetes

The reduced LBF response to exercise in the type 2 diabetic subjects was moderately well correlated with the LBF response to acetylcholine. Acetylcholine mediates vasodilation through interaction with the endothelial M3 muscarinic receptor (19) to release NO and vasodilator prostanoids, which diffuse to the underlying smooth muscle and initiate vasorelaxation (20,21). Thus, either the endothelial mechanisms for acetylcholine-stimulated release of NO or prostanoids or arterial smooth muscle reactivity to these substances is reduced in type 2 diabetic subjects. This study implicates these mechanisms in the impaired LBF response to exercise.

Although previous studies have shown impaired endothelium-independent smooth muscle responsiveness to NO in type 2 diabetic subjects (1,2), in the current and previous studies (3), responses to the direct-acting smooth muscle relaxant sodium nitroprusside were normal. This disparity most probably relates to disease severity, which was relatively mild in the current study. The relationship between LBF responses to acetylcholine and exercise therefore appears to be of endothelial origin, at least with respect to NO.

In the current study, there were trends for relationships between lipid parameters and LBF response to exercise; however, significant relationships existed for insulin, glucose, and BMI. In multiple regression analysis, plasma glucose was the only independent predictor of the LBF response to exercise. These data suggest that hyperglycemia may contribute to the impaired LBF response to exercise in type 2 diabetic subjects. Several previous studies have reported impaired forearm blood flow responses to both an ischemic stimulus (2224) and methacholine (25) during acute hyperglycemia in healthy subjects. Furthermore, acute hyperglycemia has been shown to increase blood pressure and reduce LBF, with such effects being reversible by intravenous l-arginine infusion (26). These previous findings, together with the strength of the correlation between plasma glucose and the percentage change in LBF in response to exercise in the current study, suggest that plasma glucose mediates the impaired LBF response to exercise in diabetic subjects. However, it should be noted that there was only a trend (P = 0.09) for a correlation between plasma glucose and LBF response to acetylcholine, suggesting that other mechanisms also contribute.

Mechanisms of glucose-induced endothelial dysfunction

Hyperglycemia may contribute to impaired endothelium-mediated vasodilation through multiple mechanisms. These include increased formation of oxygen-derived free radicals, activation of protein kinase C, and formation of advanced glycosylation end products (25). Advanced glycosylation end products did not appear to be important in the current study because there was no significant relationship between LBF responses to acetylcholine or exercise and HbA1c. Plasma insulin concentration at rest showed a marginally significant correlation (P = 0.05) with exercise LBF; however, this was not independent of fasting plasma glucose.

Mechanisms controlling blood flow during exercise

Despite extensive study, the precise mechanisms controlling exercise hyperemia are still unclear (rev. in 2729). Endothelium-derived vasodilator prostanoids and NO, possibly released in response to shear stress elevation, have been proposed to contribute (68); however, their role is controversial (9).

In vascular disease states, impairment of NO and vasodilator prostanoid dilatory mechanisms may have important consequences for exercise hyperemia (30). In support of this contention, an association has been made between impaired endothelium-mediated vasodilation and impaired blood flow to active muscle during exercise in hypercholesterolemic apolipoprotein-E–deficient mice (31). Although there are no comparable human studies with relevance to diabetes, it is interesting to note that lipid-lowering therapy associated with improvement in forearm-reactive hyperemia also increased ischemic threshold during treadmill testing in patients with stable angina pectoris (32). Chronic impairment in endothelium-dependent vasodilation would therefore appear to be associated with impaired exercise blood flow responses in both hypercholesterolemic mice and coronary disease patients. It is likely that impairment of NO and the vasodilator prostanoid dilatory mechanism contribute to this attenuation of exercise hyperemia, but other mechanisms may also be important. The current data provides evidence that impaired endothelium-dependent dilatory responses in relatively well-controlled patients with type 2 diabetes limits blood flow during exercise.

Clinical implications

The impaired LBF response to exercise in diabetic subjects and its relationship to acetylcholine reactivity suggests that there are important functional implications for endothelial dysfunction. Thus, although impaired endothelium-dependent dilation may be an antecedent to atherosclerosis (4) and peripheral vascular disease (4), it is also detrimental to blood flow regulation and would be expected to further exacerbate the effects of existing vascular disease in this respect. Indeed, impaired LBF response to exercise may limit exercise capacity in advanced type 2 diabetic subjects (3335). Furthermore, this may be an important mechanism contributing to reduction in leg ischemic threshold in diabetic subjects with peripheral vascular disease.

Conclusions

The LBF response during exercise is attenuated in type 2 diabetic subjects compared with matched control subjects. Impaired endothelium-dependent vasodilation secondary to elevated plasma glucose may contribute to this observation.

Figure 1—

LBF response to intrafemoral infusion of acetylcholine (A) and sodium nitroprusside (B). •, Diabetic subjects; ○ control subjects. †Significant difference between control subjects and diabetic subjects, P < 0.05.

Figure 1—

LBF response to intrafemoral infusion of acetylcholine (A) and sodium nitroprusside (B). •, Diabetic subjects; ○ control subjects. †Significant difference between control subjects and diabetic subjects, P < 0.05.

Close modal
Figure 2—

LBF (A), blood pressure (B), and leg vascular resistance (C) response to 25 min of exercise at 60% Vo2peak. BP, blood pressure; LVR, leg vascular resistance. Circles represent systolic blood pressure; squares, diastolic blood pressure; closed symbols, diabetic subjects; open symbols, control subjects. †Significant difference between control subjects and diabetic subjects, P < 0.05.

Figure 2—

LBF (A), blood pressure (B), and leg vascular resistance (C) response to 25 min of exercise at 60% Vo2peak. BP, blood pressure; LVR, leg vascular resistance. Circles represent systolic blood pressure; squares, diastolic blood pressure; closed symbols, diabetic subjects; open symbols, control subjects. †Significant difference between control subjects and diabetic subjects, P < 0.05.

Close modal
Figure 3—

Relationship between percentage change in LBF in response to acetylcholine and exercise at 60% Vo2 peak (A) and relationship between plasma glucose and percentage change in LBF in response to exercise at 60% Vo2 peak (B). Closed circles represent diabetic subjects; open circles, control subjects.

Figure 3—

Relationship between percentage change in LBF in response to acetylcholine and exercise at 60% Vo2 peak (A) and relationship between plasma glucose and percentage change in LBF in response to exercise at 60% Vo2 peak (B). Closed circles represent diabetic subjects; open circles, control subjects.

Close modal
Table 1—

Subject characteristics

Control subjectsType 2 diabetic subjectsP
Age (years) 46 ± 2 48 ± 1 0.23 
Weight (kg) 86.8 ± 4.1 88.2 ± 4.8 0.82 
BMI (kg/m225.9 ± 1.0 28.1 ± 1.4 0.25 
Systolic blood pressure (mmHg) 120 ± 2 128 ± 6 0.27 
Diastolic blood pressure (mmHg) 74 ± 2 80 ± 3 0.05* 
Fasting plasma glucose (mmol/l) 5.21 ± 0.15 9.07 ± 0.87 <0.001* 
Fasting plasma insulin (pmol/l) 61 ± 4 87 ± 18 0.20 
HbA1c (%) 4.97 ± 0.08 6.23 ± 0.38 0.005* 
Total cholesterol (mmol/l) 5.08 ± 0.22 4.75 ± 0.38 0.46 
HDL cholesterol (mmol/l) 1.39 ± 0.09 1.02 ± 0.08 0.01* 
LDL cholesterol (mmol/l) 3.25 ± 0.20 2.89 ± 0.33 0.37 
Triglycerides (mmol/l) 0.98 ± 0.14 1.82 ± 0.35 0.04* 
Vo2peak (ml · kg−1 · min−127.3 ± 2.0 28.8 ± 1.4 0.54 
Vo2 during exercise (% Vo2peak60.6 ± 1.9 60.0 ± 2.0 0.84 
Workload during exercise (W91 ± 8 97 ± 7 0.55 
Mean heart rate during exercise (beats/min) 112 ± 5 119 ± 4 0.30 
Control subjectsType 2 diabetic subjectsP
Age (years) 46 ± 2 48 ± 1 0.23 
Weight (kg) 86.8 ± 4.1 88.2 ± 4.8 0.82 
BMI (kg/m225.9 ± 1.0 28.1 ± 1.4 0.25 
Systolic blood pressure (mmHg) 120 ± 2 128 ± 6 0.27 
Diastolic blood pressure (mmHg) 74 ± 2 80 ± 3 0.05* 
Fasting plasma glucose (mmol/l) 5.21 ± 0.15 9.07 ± 0.87 <0.001* 
Fasting plasma insulin (pmol/l) 61 ± 4 87 ± 18 0.20 
HbA1c (%) 4.97 ± 0.08 6.23 ± 0.38 0.005* 
Total cholesterol (mmol/l) 5.08 ± 0.22 4.75 ± 0.38 0.46 
HDL cholesterol (mmol/l) 1.39 ± 0.09 1.02 ± 0.08 0.01* 
LDL cholesterol (mmol/l) 3.25 ± 0.20 2.89 ± 0.33 0.37 
Triglycerides (mmol/l) 0.98 ± 0.14 1.82 ± 0.35 0.04* 
Vo2peak (ml · kg−1 · min−127.3 ± 2.0 28.8 ± 1.4 0.54 
Vo2 during exercise (% Vo2peak60.6 ± 1.9 60.0 ± 2.0 0.84 
Workload during exercise (W91 ± 8 97 ± 7 0.55 
Mean heart rate during exercise (beats/min) 112 ± 5 119 ± 4 0.30 

Values are expressed as means ± SE. Blood pressures (brachial sphygmomanometry) and fasting plasma glucose and insulin were measured at the initial screening visit. Exercise was at 60% Vo2peak.

*

P < 0.05 compared with control subjects.

This work was supported by the National Health and Medical Research Council of Australia; the Alfred Hospital, Melbourne, Australia; and Diabetes Australia.

The authors thank Dr. James Shaw, Cleo Martin, Leonie Johnston, and staff from the Alfred Baker Medical Unit for their excellent technical assistance.

1
McVeigh GE, Brennan GM, Johnston GD, McDermott BJ, McGrath LT, Henry WR, Andrews JW, Hayes JR: Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus.
Diabetologia
35
:
771
–776,
1992
2
Williams SB, Cusco JA, Roddy MA, Johnstone MT, Creager MA: Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus.
J Am Coll Cardiol
27
:
567
–574,
1996
3
Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD: Obesity/insulin resistance is associated with endothelial dysfunction: implications for the syndrome of insulin resistance.
J Clin Invest
97
:
2601
–2610,
1996
4
Yu HI, Sheu WH, Lai CJ, Lee WJ, Chen YT: Endothelial dysfunction in type 2 diabetes mellitus subjects with peripheral artery disease.
Int J Cardiol
78
:
19
–25,
2001
5
Ross R: Atherosclerosis—an inflammatory disease.
N Engl J Med
340
:
115
–126,
1999
6
Koller A, Kaley G: Endothelium regulates skeletal muscle microcirculation by a blood flow velocity-sensitive mechanism.
Am J Physiol
258
:
H916
–H920,
1990
7
Koller A, Kaley G: Endothelial regulation of wall shear stress and blood flow in skeletal muscle microcirculation.
Am J Physiol
260
:
H862
–H868,
1991
8
Koller A, Dörnyei G, Kaley G: Flow-induced responses in skeletal muscle venules: modulation by nitric oxide and prostaglandins.
Am J Physiol
275
:
H831
–H836,
1998
9
Kingwell BA: Nitric oxide-mediated metabolic regulation during exercise: effects of training in health and cardiovascular disease.
FASEB J
14
:
1685
–1696,
2000
10
Boushel R, Langberg H, Gemmer C, Olesen J, Crameri R, Scheede C, Sander M, Kjaer M: Combined inhibition of nitric oxide and prostaglandins reduces human skeletal muscle blood flow during exercise.
J Physiol
543
:
691
–698,
2002
11
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus.
Diabetes Care
20
:
1183
–1197,
1997
12
Colman PG, Thomas DW, Zimmet PZ, Welborn TA, Garcia-Webb P, Moore MP: New classification and criteria for diagnosis of diabetes mellitus: position statement from the Australian Diabetes Society, New Zealand Society for the Study of Diabetes, Royal College of Pathologists of Australasia and Australasian Association of Clinical Biochemists.
Med J Aust
170
:
375
–378,
1999
13
Mather KJ, Verma S, Anderson TJ: Improved endothelial function with metformin in type 2 diabetes mellitus.
J Am Coll Cardiol
37
:
1344
–1350,
2001
14
Kingwell BA, Formosa M, Muhlmann M, Bradley SJ, McConell GK: Nitric oxide synthase inhibition reduces glucose uptake during exercise in individuals with type 2 diabetes more than in control subjects.
Diabetes
51
:
2572
–2580,
2002
15
Bradley SJ, Kingwell BA, McConell GK: Nitric oxide synthase inhibition reduces leg glucose uptake but not blood flow during dynamic exercise in humans [published erratum in Diabetes 48:2480, 1999].
Diabetes
48
:
1815
–1821,
1999
16
Andersen P, Saltin B: Maximal perfusion of skeletal muscle in man.
J Physiol (Lond)
366
:
233
–249,
1985
17
Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK, Deanfield JE: Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis.
Lancet
340
:
1111
–1115,
1992
18
Martin IK, Katz A, Wahren J: Splanchnic and muscle metabolism during exercise in NIDDM patients.
Am J Physiol
269
:
E583
–E590,
1995
19
Bruning TA, Chang PC, Hendriks MG, Vermeij P, Pfaffendorf M, van Zwieten PA: In vivo characterization of muscarinic receptor subtypes that mediate vasodilation in patients with essential hypertension.
Hypertension
26
:
70
–77,
1995
20
Lawrence RN, Clelland C, Beggs D, Salama FD, Dunn WR, Wilson VG: Differential role of vasoactive prostanoids in porcine and human isolated pulmonary arteries in response to endothelium-dependent relaxants.
Br J Pharmacol
125
:
1128
–1137,
1998
21
Noon JP, Walker BR, Hand MF, Webb DJ: Impairment of forearm vasodilatation to acetylcholine in hypercholesterolemia is reversed by aspirin.
Cardiovasc Res
38
:
480
–484,
1998
22
Akbari CM, Saouaf R, Barnhill DF, Newman PA, LoGerfo FW, Veves A: Endothelium-dependent vasodilatation is impaired in both microcirculation and macrocirculation during acute hyperglycemia.
J Vasc Surg
28
:
687
–694,
1998
23
Kawano H, Motoyama T, Hirashima O, Hirai N, Miyao Y, Sakamoto T, Kugiyama K, Ogawa H, Yasue H: Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery.
J Am Coll Cardiol
34
:
146
–154,
1999
24
Title LM, Cummings PM, Giddens K, Nassar BA: Oral glucose loading acutely attenuates endothelium-dependent vasodilation in healthy adults without diabetes: an effect prevented by vitamins C and E.
J Am Coll Cardiol
36
:
2185
–2191,
2000
25
Williams SB, Goldfine AB, Timimi FK, Ting HH, Roddy MA, Simonson DC, Creager MA: Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo.
Circulation
97
:
1695
–1701,
1998
26
Giugliano D, Marfella R, Coppola L, Verrazzo G, Acampora R, Giunta R, Nappo F, Lucarelli C, D’Onofrio F: Vascular effects of acute hyperglycemia in humans are reversed by L-arginine: evidence for reduced availability of nitric oxide during hyperglycemia.
Circulation
95
:
1783
–1790,
1997
27
Delp MD: Control of skeletal muscle perfusion at the onset of dynamic exercise.
Med Sci Sports Exerc
31
:
1011
–1018,
1999
28
Saltin B, Radegran G, Koskolou MD, Roach RC: Skeletal muscle blood flow in humans and its regulation during exercise.
Acta Physiol Scand
162
:
421
–436,
1998
29
Laughlin MH, Schrage WG: Effects of muscle contraction on skeletal muscle blood flow: when is there a muscle pump?
Med Sci Sports Exerc
31
:
1027
–1035,
1999
30
Bache RJ: Vasodilator reserve: a functional assessment of coronary health.
Circulation
98
:
1257
–1260,
1998
31
Maxwell A, Schauble E, Bernstein D, Cooke J: Limb blood flow during exercise is dependent on nitric oxide.
Circulation
98
:
369
–374,
1998
32
de Divitiis M, Rubba P, Di Somma S, Liguori V, Galderisi M, Montefusco S, Carreras G, Greco V, Carotenuto A, Iannuzzo G, de Divitiis O: Effects of short-term reduction in serum cholesterol with simvastatin in patients with stable angina pectoris and mild to moderate hypercholesterolemia.
Am J Cardiol
78
:
763
–768,
1996
33
Katoh J, Hara Y, Kurusu M, Miyaji J, Narutaki K: Cardiorespiratory function as assessed by exercise testing in patients with non-insulin-dependent diabetes mellitus.
J Int Med Res
24
:
209
–213,
1996
34
Estacio RO, Wolfel EE, Regensteiner JG, Jeffers B, Havranek EP, Savage S, Schrier RW: Effect of risk factors on exercise capacity in NIDDM.
Diabetes
45
:
79
–85,
1996
35
Estacio RO, Regensteiner JG, Wolfel EE, Jeffers B, Dickenson M, Schrier RW: The association between diabetic complications and exercise capacity in NIDDM patients.
Diabetes Care
21
:
291
–295,
1998

Address correspondence and reprint requests to Dr. Bronwyn Kingwell, Alfred and Baker Medical Unit, Baker Medical Research Institute, Wynn Domain, P.O. Box 6492 St Kilda Rd. Central, Melbourne 8008, Australia. E-mail: b.kingwell@alfred.org.au.

Received for publication 1 August 2002 and accepted in revised form 19 November 2002.

A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.